Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Lifecore Biomedical (LFCR) over the last 17 years, with May 2025 value amounting to $10.2 million.

  • Lifecore Biomedical's Share-based Compensation rose 13.58% to $1.8 million in Q2 2025 from the same period last year, while for May 2025 it was $10.2 million, marking a year-over-year increase of 63.81%. This contributed to the annual value of $10.2 million for FY2025, which is 63.81% up from last year.
  • Lifecore Biomedical's Share-based Compensation amounted to $10.2 million in FY2025, which was up 63.81% from $6.2 million recorded in FY2024.
  • In the past 5 years, Lifecore Biomedical's Share-based Compensation registered a high of $10.2 million during FY2025, and its lowest value of $2.6 million during FY2022.
  • In the last 3 years, Lifecore Biomedical's Share-based Compensation had a median value of $6.2 million in 2024 and averaged $6.7 million.
  • Per our database at Business Quant, Lifecore Biomedical's Share-based Compensation dropped by 22.38% in 2022 and then soared by 71.68% in 2024.
  • Lifecore Biomedical's Share-based Compensation (Yearly) stood at $3.4 million in 2021, then declined by 22.38% to $2.6 million in 2022, then spiked by 38.50% to $3.6 million in 2023, then skyrocketed by 71.68% to $6.2 million in 2024, then surged by 63.81% to $10.2 million in 2025.